Multi-component biomarkers: what are they, and why does it matter? While they are increasingly common in medicine – especially in drug development – there are no “official” definitions yet of…
Read More
Koneksa was privileged recently to present at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) alongside colleagues from the U.S. Food & Drug Administration (FDA)…
I was delighted to join several of my Koneksa colleagues in person at the recent 13th Summit for Clinical Ops Executives (SCOPE) conference in Orlando, Florida. The focus SCOPE has…
Recently, the FDA released draft guidance for comment on remote digital data acquisition in clinical trials. The applications of digital health technologies (DHT) in clinical trials gained traction over the…
Today, we announced the completion of our Series C financing round, as well as the appointment of industry leader John A. Wagner, M.D., Ph.D. as our first Chief Medical Officer….
The digital field has been greatly transformed during the 18 months of the pandemic. The timid pre-pandemic attempts to test and explore digital health technologies (DHT) were swiftly replaced by…
As the use of wearables in clinical research grows, the Apple Watch is increasingly being evaluated for use in drug development trials. Its combination of capabilities and qualities – including…
At-home pulse oximeters have become a topic of discussion during the COVID-19 pandemic, prompting questions about OTC device reliability and the quality of remotely collected patient data. Learn more about…
Summary: Learn more about the shift from in-clinic to remote pulse oximetry and understand the real-world impact of DiMe’s Playbook in an informative digest from Koneksa. The COVID-19 pandemic has…
The Foundation for the National Institutes of Health (FNIH) is an organization that creates and leads alliances and public-private partnerships to support biomedical research, fighting disease in the United States…
